Abeona Therapeutics

Abeona Therapeutics is a publicly traded gene and cell therapy company headquartered in New York, New York. Founded in 2006, the company currently employs 81 individuals. Abeona Therapeutics specializes in the research, development, and manufacture of novel gene and cell therapies. They offer a range of products and services, including gene therapy candidates for lysosomal storage diseases and a gene-corrected cell therapy poised to enter Phase 3 clinical trials. Their expertise spans the entire process from discovery to delivery, with a focus on developing innovative solutions for a variety of genetic diseases. A key differentiator for Abeona Therapeutics is their AIM™ Vector Platform, which comprises over 100 next-generation AAV capsids designed to deliver gene therapies with improved efficiency and targeting. This platform enables them to address a wide range of organs and delivery methods, expanding their therapeutic potential across various disease areas. For inquiries and more information, please visit their website at abeonatherapeutics.com.